FDA catalysts, PDUFA dates with approval probability, drug pipeline, cash runway and insider activity — updated automatically from SEC, FDA and ClinicalTrials.gov data.
| Drug | Indication | Phase | Status |
|---|---|---|---|
| ANX005 | Guillain-Barre Syndrome | PHASE3 | COMPLETED |
| Tanruprubart | Guillain-Barre Syndrome | PHASE3 | RECRUITING |
| Vonaprument | Geographic Atrophy | PHASE3 | ACTIVE_NOT_RECRUITING |
| ANX007 | Geographic Atrophy | PHASE2 | COMPLETED |
| 2.5mg ANX007 | Open Angle Glaucoma | PHASE1 | COMPLETED |
| 5.0mg ANX007 | Open Angle Glaucoma | PHASE1 | COMPLETED |
| ANX009 | Lupus Nephritis | PHASE1 | COMPLETED |
| ANX105 | Healthy | PHASE1 | COMPLETED |
| ANX1502 | Healthy | PHASE1 | COMPLETED |
| Intravenous immunoglobulin | Guillain-Barré Syndrome | PHASE1 | COMPLETED |
ANNX holds $199.3M in cash and burns about $47.4M/quarter from operations, giving an estimated runway of 12.6 months. A recent offering filing was detected — dilution watch.
Source: SEC EDGAR XBRL (operating cash flow). Get dilution alerts for ANNX free →
| Date | Insider | Type | Value |
|---|---|---|---|
| 2026-08-12 | Blumenkranz Mark S. |
Purchase | $0 |
| 2026-06-15 | Satter Muneer A |
Purchase | $0 |
| 2026-06-15 | JONES WILLIAM A JR |
Purchase | $0 |
| 2026-06-15 | Waddill William D. |
Purchase | $0 |
| 2026-06-15 | Choi Jung |
Purchase | $0 |
A free BioRadar account adds AI daily briefings, sentiment tracking, trial enrollment progress, and email alerts for ANNX and 2 more tickers of your choice.
Create Free Account →